Moderna Inc

This committee provides crucial technical analysis and 'revenue estimates' for all tax legislation, directly influencing corporate tax structures and capital investment credits, which have a substantial impact on Moderna's financial planning and bottom line.

This powerful committee controls taxation, trade policy, and entitlement spending (e.g., Medicare pricing for drugs), all of which directly and significantly impact Moderna's profitability and market access.

This committee allocates discretionary federal spending, directly determining funding for health research (e.g., NIH, BARDA, CDC) and public health initiatives, which can significantly impact Moderna's contracts and opportunities.

This committee directly regulates the FDA, which is responsible for the approval of Moderna's biological products, and influences NIH funding for crucial research. It's a primary regulatory body.

This committee's oversight of intellectual property (patents) is absolutely critical for a biotech company like Moderna. Antitrust enforcement also impacts potential M&A in the sector.

Moderna's products often target older populations (e.g., vaccines for RSV, flu, COVID). This committee's hearings on drug pricing and healthcare costs create significant 'headline risk' and influence legislative pressure on a key revenue driver.

Members receive classified briefings on global threats. For a biological product manufacturer, information on emerging pandemics, bioweapons, or global health crises would be highly material and non-public, directly impacting the company's strategic value and stock performance.